BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study
- 24 August 2010
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 16 (5), 731-739
- https://doi.org/10.1111/j.1365-2516.2010.02239.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIIIHaemophilia, 2009
- Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophiliaHaemophilia, 2009
- Immune Response to FVIII in Hemophilia A: An Overview of Risk FactorsClinical Reviews in Allergy & Immunology, 2009
- In vitro evaluation of B-domain deleted recombinant factor VIII (ReFactoR) stability during simulated continuous infusion administrationHaemophilia, 2005
- Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experienceHaemophilia, 2004
- Prevention of Venous ThromboembolismSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004
- Isolation of a peptide ligand for affinity purification of factor VIII using phage displayJournal of Chromatography A, 2004
- Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe*Transfusion, 2003
- Continuous Infusion of Coagulation Factor ProductsAnnals of Pharmacotherapy, 2002
- Adjusted dose continuous infusion of factor VIII in patients with haemophilia ABritish Journal of Haematology, 1992